GO
Loading...

AstraZeneca PLC

More

  • New kind of trial aims to speed cancer drug development Wednesday, 16 Apr 2014 | 7:01 PM ET

    *AstraZeneca, Pfizer, UK charity link in multi-drug trial. Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.

  • April 15- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.

  • FDA approves GSK's Tanzeum to treat type 2 diabetes Tuesday, 15 Apr 2014 | 10:35 AM ET

    April 15- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's Tanzeum injection for treating adults with type 2 diabetes, in combination with diet and exercise. However, it is unknown whether Tanzeum causes thyroid C-cell tumors, the FDA said on its website.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • April 10- Rite Aid Corp, the third-largest U.S. drugstore operator, forecast fiscal 2015 sales above analysts' estimates as it benefits from the launch of new generic drugs and enrolls more customers in its loyalty programs.

  • *Investors to get 0.8 Sun Pharma share per Ranbaxy share.

  • *AstraZeneca moving global HQ and R&D to Cambridge by 2016. CAMBRIDGE, England, March 31- AstraZeneca, which will complete its move to Cambridge by 2016, is already putting down roots in the ecosystem of the university city as it seeks to revitalise its drug research.

  • LONDON, March 27- Britain's healthcare agency NICE, which determines the use of treatments in the state-run health service, may be more likely to say' yes' to new drugs under proposals that enable it to take a broader view of the value they offer.

  • AstraZeneca raises bet on Japan by buying out Sumitomo Wednesday, 26 Mar 2014 | 3:21 AM ET

    LONDON, March 26- AstraZeneca has raised its bet on Japan's drug market by buying out the remaining stake held by Sumitomo Chemical in its Japanese unit AstraZeneca K.K. The British group said on Wednesday the purchase of the shares cost approximately 10 billion yen and reinforced its focus on Japan as a key growth platform.

  • PARIS/ MOSCOW, March 21- U.S. and European sanctions against Russia are already having a ripple effect beyond their immediate targets, with Visa and MasterCard halting payment transaction services for clients of a bank not even on the blacklist. The lender described the move by Visa and MasterCard as unlawful.

  • Rivals race to develop new biotech asthma drugs Tuesday, 18 Mar 2014 | 8:48 AM ET

    *Rivals include Roche, AstraZeneca, Sanofi and Teva. LONDON, March 18- Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

  • *Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.

  • MUMBAI/ LONDON, March 11- Indian drugmaker Ranbaxy Laboratories Ltd is in talks with at least two companies on sourcing ingredients for a generic version of AstraZeneca Plc's heartburn drug Nexium, a source said, to ensure the pills can be sold in the United States.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron Pharmaceuticals Inc and Sanofi SA to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday.

  • March 7- The U.S. Food and Drug Administration has asked Regeneron and Sanofi to assess potential neurocognitive side effects of their experimental cholesterol drug, Sanofi said in its annual report on Friday. U.S.-listed shares of France- based Sanofi were down 1 percent.

  • Feb 25- Bristol-Myers Squibb Co said the U.S. Food and Drug Administration approved its drug to treat rare and potentially fatal disorders involving loss of body fat. Bristol-Myers said the FDA had asked it to conduct seven post-marketing studies on Myalept. The drugmaker had co-developed the drug with AstraZeneca.

  • *FDA chief says important for India to work with foreign regulators. MUMBAI, Feb 18- The head of the U.S. Food and Drug Administration called for more collaboration among regulators to improve drug quality and safety as she wrapped up a visit to India after recent import bans on drugs from a handful of plants in the country.

  • *More drugmakers could opt not to launch drugs in Germany. FRANKFURT/ BERLIN, Feb 18- Germany's plan to publish price discounts agreed with drugmakers poses a risk to profits in the industry, which fears the information could be used to drive down prices elsewhere.

  • Feb 11- The U.S. Food and Drug Administration said it will review possible heart risks associated with AstraZeneca Plc's widely-used diabetes drug saxagliptin, marketed as Onglyza and Kombiglyze XR.

  • BUSINESS-NEWS-SCHEDULE AT 1530 GMT / 10.30 AM ET Thursday, 6 Feb 2014 | 10:35 AM ET

    DETROIT- General Motors reported a weaker-than-expected fourth-quarter profit on Thursday as results in North America, Asia and South America disappointed, sending shares down about 2 percent in morning trading. Noble Energy's weak production forecast surprises Wall Street.

Most Popular Video

Thursday, 17 Apr 2014 | 12:00 PM ET

CNBC's Josh Lipton and Allison+Partners Head of Digital Jeremy Rosenberg discuss what Microsoft needs to do to boost Xbox One sales as PS4 sales break the 7 million mark.

Thursday, 17 Apr 2014 | 4:13 PM ET

Dissecting today's market activity and the current state of financials, with Yra Harris, Praxis Trading partner; Larry Glazer, Mayflower Advisors; CNBC contributor Carol Roth; "Fast Money" Guy Adami and CNBC's Kate Kelly.

Thursday, 17 Apr 2014 | 5:46 PM ET

CNBC voice over talent Jim Birdsall shares the top 5 sayings from traders on "Fast Money" over the years.